Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BIMO Inspections Increase, Warning Letters Decrease In Fiscal 2002

This article was originally published in The Gray Sheet

Executive Summary

The device center's bioresearch monitoring division conducted 90 more inspections during fiscal year 2002 than it did in 2001

You may also be interested in...



BIMO Plans FY ’04 Device Projects: Web Tutorial, Foreign Data Assessment

A web-based tutorial for clinical investigators is among initiatives the FDA device center's bioresearch monitoring (BIMO) division envisions for FY 2004

BIMO Plans FY ’04 Device Projects: Web Tutorial, Foreign Data Assessment

A web-based tutorial for clinical investigators is among initiatives the FDA device center's bioresearch monitoring (BIMO) division envisions for FY 2004

CDRH BIMO Turning Over New Leaf With “Paperless Project” Pilot

The CDRH Bioresearch Monitoring division's "paperless project" pilot is a step toward greater use of electronic media by the division, staffers suggest

UsernamePublicRestriction

Register

OM004967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel